PMID- 19635146
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20240408
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 2
DP  - 2009 Jul 27
TI  - Vorinostat in solid and hematologic malignancies.
PG  - 31
LID - 10.1186/1756-8722-2-31 [doi]
AB  - Vorinostat (Zolinza), a histone deacetylase inhibitor, was approved by the US 
      Food and Drug Administration in October 2006 for the treatment of cutaneous 
      manifestations in patients with cutaneous T-cell lymphoma who have progressive, 
      persistent or recurrent disease on or following two systemic therapies. This 
      review summarizes evidence on the use of vorinostat in solid and hematologic 
      malignancies and collated tolerability data from the vorinostat clinical trial 
      program. Pooled vorinostat clinical trial data from 498 patients with solid or 
      hematologic malignancies show that vorinostat was well tolerated as monotherapy 
      or combination therapy. The most commonly reported drug-related adverse events 
      (AEs) associated with monotherapy (n = 341) were fatigue (61.9%), nausea (55.7%), 
      diarrhea (49.3%), anorexia (48.1%), and vomiting (32.8%), and Grade 3/4 
      drug-related AEs included fatigue (12.0%), thrombocytopenia (10.6%), dehydration 
      (7.3%), and decreased platelet count (5.3%). The most common drug-related AEs 
      observed with vorinostat in combination therapy (n = 157, most of whom received 
      vorinostat 400 mg qd for 14 days) were nausea (48.4%), diarrhea (40.8%), fatigue 
      (34.4%), vomiting (31.2%), and anorexia (20.4%), with the majority of AEs being 
      Grade 2 or less. In Phase I trials, combinations with vorinostat were generally 
      well tolerated and preliminary evidence of anticancer activity as monotherapy or 
      in combination with other systemic therapies has been observed across a range of 
      malignancies. Ongoing and planned studies will further evaluate the potential of 
      vorinostat in combination therapy, including combinations with radiation, in 
      patients with diverse malignancy types, including non-small-cell lung cancer, 
      glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome.
FAU - Siegel, David
AU  - Siegel D
AD  - Hackensack University Medical Center, Hackensack, NJ, USA. dsiegel@humed.com
FAU - Hussein, Mohamad
AU  - Hussein M
FAU - Belani, Chandra
AU  - Belani C
FAU - Robert, Francisco
AU  - Robert F
FAU - Galanis, Evanthia
AU  - Galanis E
FAU - Richon, Victoria M
AU  - Richon VM
FAU - Garcia-Vargas, Jose
AU  - Garcia-Vargas J
FAU - Sanz-Rodriguez, Cesar
AU  - Sanz-Rodriguez C
FAU - Rizvi, Syed
AU  - Rizvi S
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Review
DEP - 20090727
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hydroxamic Acids)
RN  - 58IFB293JI (Vorinostat)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/adverse effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Hematologic Neoplasms/*drug therapy
MH  - Humans
MH  - Hydroxamic Acids/adverse effects/*therapeutic use
MH  - Models, Biological
MH  - Neoplasms/*drug therapy
MH  - Vorinostat
PMC - PMC2731787
EDAT- 2009/07/29 09:00
MHDA- 2010/06/16 06:00
PMCR- 2009/07/27
CRDT- 2009/07/29 09:00
PHST- 2009/05/29 00:00 [received]
PHST- 2009/07/27 00:00 [accepted]
PHST- 2009/07/29 09:00 [entrez]
PHST- 2009/07/29 09:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
PHST- 2009/07/27 00:00 [pmc-release]
AID - 1756-8722-2-31 [pii]
AID - 10.1186/1756-8722-2-31 [doi]
PST - epublish
SO  - J Hematol Oncol. 2009 Jul 27;2:31. doi: 10.1186/1756-8722-2-31.